The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review
Topic. The aim of this study is to evaluate the efficacy of conbercept in PCV, which will optimize the management for PCV patients. Clinical Relevance. The use of antivascular endothelial growth factor (VEGF) therapy in polypoidal choroidal vasculopathy (PCV), a subtype of neovascular age-related ma...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2020/4924053 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565841068032000 |
|---|---|
| author | Yimin Wang Mengxi Shen Jinwei Cheng Xiaodong Sun Peter K. Kaiser |
| author_facet | Yimin Wang Mengxi Shen Jinwei Cheng Xiaodong Sun Peter K. Kaiser |
| author_sort | Yimin Wang |
| collection | DOAJ |
| description | Topic. The aim of this study is to evaluate the efficacy of conbercept in PCV, which will optimize the management for PCV patients. Clinical Relevance. The use of antivascular endothelial growth factor (VEGF) therapy in polypoidal choroidal vasculopathy (PCV), a subtype of neovascular age-related macular degeneration (nAMD), has been well established in randomized clinical trials. This meta-analysis has evaluated the efficacy of a novel anti-VEGF agent, conbercept, in the management of PCV using ranibizumab and aflibercept as the reference agents. Methods. Thirty studies with 1308 eyes were identified and included in this study. The primary outcome measures were best-corrected visual acuity (BCVA), and secondary outcomes were optical coherence tomography characteristics and polyp regression rates. The pooled results were calculated by the random-effect or fixed-effect model according to the heterogeneity of the data. Results. Despite a large standard deviation in means (SMD) improvement for BCVA and central retinal thickness (CRT) in the conbercept group, there was no statistically significant difference in the other outcomes compared to ranibizumab and aflibercept. However, there was a greater polyp regression rate in the conbercept group at 12 months. Conclusions. This systematic review indicates that conbercept may achieve similar BCVA and CRT improvements as ranibizumab and aflibercept, with a superior rate of polyp regression at 12 months. |
| format | Article |
| id | doaj-art-1ad7375c9dad42e0bf470969d7dbde82 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-1ad7375c9dad42e0bf470969d7dbde822025-02-03T01:06:23ZengWileyJournal of Ophthalmology2090-004X2090-00582020-01-01202010.1155/2020/49240534924053The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic ReviewYimin Wang0Mengxi Shen1Jinwei Cheng2Xiaodong Sun3Peter K. Kaiser4Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USADepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaCole Eye Institute, Cleveland, OH, USATopic. The aim of this study is to evaluate the efficacy of conbercept in PCV, which will optimize the management for PCV patients. Clinical Relevance. The use of antivascular endothelial growth factor (VEGF) therapy in polypoidal choroidal vasculopathy (PCV), a subtype of neovascular age-related macular degeneration (nAMD), has been well established in randomized clinical trials. This meta-analysis has evaluated the efficacy of a novel anti-VEGF agent, conbercept, in the management of PCV using ranibizumab and aflibercept as the reference agents. Methods. Thirty studies with 1308 eyes were identified and included in this study. The primary outcome measures were best-corrected visual acuity (BCVA), and secondary outcomes were optical coherence tomography characteristics and polyp regression rates. The pooled results were calculated by the random-effect or fixed-effect model according to the heterogeneity of the data. Results. Despite a large standard deviation in means (SMD) improvement for BCVA and central retinal thickness (CRT) in the conbercept group, there was no statistically significant difference in the other outcomes compared to ranibizumab and aflibercept. However, there was a greater polyp regression rate in the conbercept group at 12 months. Conclusions. This systematic review indicates that conbercept may achieve similar BCVA and CRT improvements as ranibizumab and aflibercept, with a superior rate of polyp regression at 12 months.http://dx.doi.org/10.1155/2020/4924053 |
| spellingShingle | Yimin Wang Mengxi Shen Jinwei Cheng Xiaodong Sun Peter K. Kaiser The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review Journal of Ophthalmology |
| title | The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review |
| title_full | The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review |
| title_fullStr | The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review |
| title_full_unstemmed | The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review |
| title_short | The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review |
| title_sort | efficacy of conbercept in polypoidal choroidal vasculopathy a systematic review |
| url | http://dx.doi.org/10.1155/2020/4924053 |
| work_keys_str_mv | AT yiminwang theefficacyofconberceptinpolypoidalchoroidalvasculopathyasystematicreview AT mengxishen theefficacyofconberceptinpolypoidalchoroidalvasculopathyasystematicreview AT jinweicheng theefficacyofconberceptinpolypoidalchoroidalvasculopathyasystematicreview AT xiaodongsun theefficacyofconberceptinpolypoidalchoroidalvasculopathyasystematicreview AT peterkkaiser theefficacyofconberceptinpolypoidalchoroidalvasculopathyasystematicreview AT yiminwang efficacyofconberceptinpolypoidalchoroidalvasculopathyasystematicreview AT mengxishen efficacyofconberceptinpolypoidalchoroidalvasculopathyasystematicreview AT jinweicheng efficacyofconberceptinpolypoidalchoroidalvasculopathyasystematicreview AT xiaodongsun efficacyofconberceptinpolypoidalchoroidalvasculopathyasystematicreview AT peterkkaiser efficacyofconberceptinpolypoidalchoroidalvasculopathyasystematicreview |